CN103356535A - Application of Sarcaboside A in preparation of drug for treating pancreatic cancer - Google Patents
Application of Sarcaboside A in preparation of drug for treating pancreatic cancer Download PDFInfo
- Publication number
- CN103356535A CN103356535A CN 201310262734 CN201310262734A CN103356535A CN 103356535 A CN103356535 A CN 103356535A CN 201310262734 CN201310262734 CN 201310262734 CN 201310262734 A CN201310262734 A CN 201310262734A CN 103356535 A CN103356535 A CN 103356535A
- Authority
- CN
- China
- Prior art keywords
- sarcaboside
- drug
- pancreatic cancer
- preparation
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- WPNBVFPCYFPKOW-SWGJQYNISA-N CC(/C=C/C(/C)=N\CC(OC)=O)(/C=C(\CC(C)(COC(CC(C)(C/C=[U]1)OC)=O)C1=O)/OC)C(OC)=O Chemical compound CC(/C=C/C(/C)=N\CC(OC)=O)(/C=C(\CC(C)(COC(CC(C)(C/C=[U]1)OC)=O)C1=O)/OC)C(OC)=O WPNBVFPCYFPKOW-SWGJQYNISA-N 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses application of Sarcaboside A in preparation of a drug for treating pancreatic cancer, which belongs to the technical field of new applications of drug. According to the invention, the in-vitro MTT (Methyl Thiazolyl Tetrazolium) antitumor activity evaluation discovers that Sarcaboside A also has an obvious inhibiting effect on the growth of human pancreatic cancer cell strains PANC-1 and BXPC-3. Thus, Sarcaboside A can be used for preparing an anti-pancreatic cancer drug and has good development and application prospects. The application of Sarcaboside A in preparation of the drug for treating pancratic cancer is disclosed by the invention for the first time. The skeleton type is brand new and Sarcaboside A has unexpectedly strong inhibitory activity to the human pancreatic cancer cell.
Description
Technical field
The present invention relates to the new purposes of compound S arcaboside A, relate in particular to the application of Sarcaboside A in the anti-cancer of pancreas medicine of preparation.
Technical background
Cancer is to one of disease of human life's health hazard maximum, and annual have a large amount of people to die from cancer.The research and development of cancer therapy drug are the focuses of study of pharmacy always.Having 74% to be the natural product or derivatives thereof in the antitumor drug, is exactly the present reasonable antitumor drug of effect clinically such as paclitaxel and derivant thereof.Therefore, searching anticancer compound or lead compound have great importance from natural product.
The compound S arcaboside A that the present invention relates to is one and delivered (Li in 2012, X. et al., 2012. Two New-Skeleton Compounds from Sarcandra glabra. Helvetica Chimica Acta 95 (6), 998-1002.) New skeleton compound, this chemical compound has brand-new framework types, there is not at present the report about activity, belong to open first for the purposes of the Sarcaboside A that the present invention relates in preparation treatment cancer of pancreas medicine, because framework types belongs to brand-new framework types, and its inhibition for pancreatic cancer cell is active unexpectedly strong, there is not the possibility that is provided any enlightenment by other chemical compounds, possess outstanding substantive distinguishing features, the control that is used for simultaneously cancer of pancreas obviously has significant progress.
Summary of the invention
The invention provides the application of compound S arcaboside A in the preparation antitumor drug.
The present invention adopts following technical scheme: the application of Sarcaboside A in the anti-cancer of pancreas medicine of preparation, and the structural formula of Sarcaboside A is shown in formula I:
Formula I
The present invention finds by external MTT anti-tumor activity evaluation, and Sarcaboside A also has significant inhibitory action to the growth of human pancreas cancer cell strain PANC-1 and BXPC-3, suppresses the IC of this 2 strain Growth of Cells
50Value is respectively 1.06 ± 0.18 μ M and 1.26 ± 0.27 μ M.Therefore, Sarcaboside A can for the preparation of anti-cancer of pancreas medicine, have good development prospect.
Belong to open first for the purposes of the Sarcaboside A that the present invention relates in preparation treatment cancer of pancreas medicine, because framework types belongs to brand-new framework types, and its inhibition for pancreatic cancer cell is active unexpectedly strong, there is not the possibility that is provided any enlightenment by other chemical compounds, possess outstanding substantive distinguishing features, the control that is used for simultaneously cancer of pancreas obviously has significant progress.
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subjected to any restriction of specific embodiment, but limited by claim.
The specific embodiment
The preparation method of compound S arcaboside A involved in the present invention is referring to document (Li, X. et al., 2012. Two New-Skeleton Compounds from Sarcandra glabra. Helvetica Chimica Acta 95 (6), 998-1002.).
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subjected to any restriction of specific embodiment, but limited by claim.
Embodiment 1: the preparation of compound S arcaboside A tablet involved in the present invention:
Get 20 and digest compound Sarcaboside A, add conventional adjuvant 180 grams of preparation tablet, mixing, conventional tablet machine are made 1000.
Embodiment 2: the preparation of compound S arcaboside A capsule involved in the present invention:
Get 20 and digest compound Sarcaboside A, add conventional adjuvant such as starch 180 grams of preparation capsule, mixing is encapsulatedly made 1000.
Further specify its pharmaceutically active below by pharmacodynamic experiment.
Experimental example: adopt mtt assay assessing compound Sarcaboside A to the growth inhibited effect of human pancreas cancer cell strain
1. method: the cell that is in the growth logarithmic (log) phase: human pancreas cancer cell strain PANC-1 and BXPC-3(buy from Chinese Academy of Sciences's cell bank) with 1.5 * 10
4The concentration kind is in 96 orifice plates.Suck original culture medium after cell culture 24 h are adherent.Test is divided into blank group, drug treating group.Blank group is changed 1640 culture medium that contain 10% hyclone; It is 100 μ M that the replacing of drug treating group contains concentration, 50 μ M, 10 μ M, 1 μ M, 0.1 μ M, the culture medium of the Sarcaboside A of 0.01 μ M and 0.001 μ M.After cultivating 48 h, add the MTT of concentration 5 mg/mL, continue to be put in CO
2Incubator is cultivated 4 h, then suck 100 μ L supernatants along culture fluid top, add 100 μ L DMSO, 10 min are placed in the dark place, utilize microplate reader (Sunrise company product) to measure light absorption value (wavelength 570nm), and according to light absorption value calculating cell survival situation, 6 repeating holes are established in each processing.Cell survival rate (%)=Δ OD
Drug treating/ Δ OD
Blank* 100.
2. result: Sarcaboside A has significant inhibitory action to the growth of human pancreas cancer cell strain PANC-1 and BXPC-3.This chemical compound suppresses the IC of human pancreas cancer cell strain PANC-1 and BXPC-3 growth
50Value is respectively 1.06 ± 0.18 μ M and 1.26 ± 0.27 μ M.
Shown by above-described embodiment, Sarcaboside A of the present invention has good inhibitory action to the growth of human pancreas cancer cell strain PANC-1 and BXPC-3.Prove thus, it is active that Sarcaboside A of the present invention has anti-cancer of pancreas, can be for the preparation of anti-cancer of pancreas medicine.
Claims (1)
1.Sarcaboside the application of A in treatment cancer of pancreas medicine, described compound S arcaboside A structure as
Formula IShown in:
Formula I.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201310262734 CN103356535A (en) | 2013-06-27 | 2013-06-27 | Application of Sarcaboside A in preparation of drug for treating pancreatic cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201310262734 CN103356535A (en) | 2013-06-27 | 2013-06-27 | Application of Sarcaboside A in preparation of drug for treating pancreatic cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103356535A true CN103356535A (en) | 2013-10-23 |
Family
ID=49359357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201310262734 Pending CN103356535A (en) | 2013-06-27 | 2013-06-27 | Application of Sarcaboside A in preparation of drug for treating pancreatic cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103356535A (en) |
-
2013
- 2013-06-27 CN CN 201310262734 patent/CN103356535A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102885809B (en) | Application of Aphanamixoid A in preparing medicament for treating pancreatic cancer | |
| CN102872089B (en) | Application of Houttuynoid E in preparing medicines for treating skin cancer | |
| CN102872122B (en) | Application of Houttuynoid B in medicament for treating pancreatic cancer | |
| CN102872093B (en) | Application of Houttuynoid E in medicine for treating pancreatic cancer | |
| CN102872111B (en) | Application of Houttuynoid C in medicament for treating pancreatic cancer | |
| CN102861059B (en) | Application of Houttuynoid D in pancreatic cancer treatment medicine | |
| CN102861050A (en) | Application of Houttuynoid A in medicine for treating pancreatic cancer | |
| CN102872148B (en) | Application of Houttuynoid D in medicament for treating tongue cancer | |
| CN103356535A (en) | Application of Sarcaboside A in preparation of drug for treating pancreatic cancer | |
| CN103356538A (en) | Application of Sarcaboside A in preparation of drug for treating ovarian cancer | |
| CN103356545A (en) | Application of Sarcaboside B in medicine used for treating ovarian cancer | |
| CN103356589A (en) | Application of Sarcaboside A in preparation of drug for treating cervical cancer | |
| CN103356578A (en) | Application of Sarcaboside A in preparation of drug for treating bile duct carcinoma | |
| CN103356577A (en) | Application of Sarcaboside A in preparation of drug for treating stomach cancer | |
| CN103356553A (en) | Application of Sarcaboside A in preparation of drug for treating breast cancer | |
| CN103356534A (en) | Application of Sarcaboside B in medicine used for treating colorectal cancer | |
| CN103393668A (en) | Application of Sarcaboside B to medicament for treatment of pancreas cancer | |
| CN103356539A (en) | Application of Sarcaboside A in preparation of drug for treating colorectal cancer | |
| CN103356547A (en) | Application of Sarcaboside A in preparation of drug for treating skin cancer | |
| CN103463032A (en) | Application of Lycojaponicumin A in medicine for treating pancreatic cancer | |
| CN103356531A (en) | Application of Sarcaboside B in medicine used for treating cervical cancer | |
| CN103356550A (en) | Application of Sarcaboside B in medicine used for treating laryngeal cancer | |
| CN103446142A (en) | Application of Lycojaponicumin C in pancreatic cancer treatment drug | |
| CN103356532A (en) | Application of Sarcaboside B in medicine used for treating breast cancer | |
| CN103356568A (en) | Application of Sarcaboside A in preparing medicine for treating tongue cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20131023 |